Q2 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for REGENXBIO in a research report issued to clients and investors on Monday, May 19th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($0.89) for the quarter, up from their previous estimate of ($1.47). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at ($1.48) EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($3.03) EPS, FY2028 earnings at ($2.22) EPS and FY2029 earnings at ($1.15) EPS.

Several other research firms also recently weighed in on RGNX. Wall Street Zen upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Raymond James began coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. HC Wainwright cut their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Finally, Morgan Stanley raised their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Down 5.4%

NASDAQ RGNX traded down $0.52 on Thursday, hitting $9.19. The company's stock had a trading volume of 660,163 shares, compared to its average volume of 882,260. The company's 50-day moving average is $7.85 and its 200 day moving average is $7.98. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $15.39. The firm has a market cap of $460.97 million, a PE ratio of -1.84 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The firm had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.

Institutional Trading of REGENXBIO

A number of large investors have recently made changes to their positions in RGNX. FNY Investment Advisers LLC bought a new position in REGENXBIO in the first quarter worth about $35,000. Brooklyn Investment Group boosted its position in REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 3,466 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in REGENXBIO in the 4th quarter worth approximately $54,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of REGENXBIO during the 4th quarter valued at approximately $79,000. Finally, Laurion Capital Management LP acquired a new stake in shares of REGENXBIO in the fourth quarter valued at about $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now owns 475,103 shares in the company, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.79% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.